Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
IPO Year: 2016
Exchange: NASDAQ
Website: protagonist-inc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $72.00 | Buy | Citigroup |
| 12/6/2024 | $47.00 | Neutral | Goldman |
| 12/6/2024 | $62.00 | Outperform | BMO Capital Markets |
| 11/5/2024 | $58.00 | Outperform | Wedbush |
| 9/24/2024 | $65.00 | Buy | TD Cowen |
| 9/9/2024 | $60.00 | Buy | Truist |
| 10/30/2023 | $32.00 | Overweight | CapitalOne |
| 5/25/2023 | $30.00 → $40.00 | Buy | Jefferies |
| 8/25/2022 | $21.00 | Mkt Outperform | JMP Securities |
| 2/11/2022 | $55.00 | Buy | BTIG |
SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)
S-3ASR - Protagonist Therapeutics, Inc (0001377121) (Filer)
10-Q - Protagonist Therapeutics, Inc (0001377121) (Filer)
8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)
144 - Protagonist Therapeutics, Inc (0001377121) (Subject)
8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)
SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)
SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)
10-Q - Protagonist Therapeutics, Inc (0001377121) (Filer)
8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
Fastest customizable press release news feed in the world
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig
− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou
NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter. Dr. Yeilding served in a consultant role as the Company's Chief Scientific Advisor from August 1, 2024 through January 1, 2025. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.Dr. Yeilding received options to purchase 38,520 sh
NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a company overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 12-16, 2025 in San Francisco, CA. The Company will also participate in one-on-one meetings.43rd Annual J.P. Morgan Healthcare Conference - January 12-16, 2025Format: Company PresentationDay/Time: Tuesday, January 14 at 8:15AM PTWebcast: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58274-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=trueIf you are interested in meeting
Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives
54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and improvements in patient-reported outcomes in patients with polycythemia vera NEWARK, CA / ACCESSWIRE / December 9, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced details from a poster presentation with final data from the rusfertide Phase 2 REVIVE study. Rusfertide, a mimetic of the natural hormone hepcidin, has potential therapeutic value in the treatment of polycythemia vera (PV) and other disease indications. The data were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, t
NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference taking place December 3-5, 2024 in Coral Gables, Florida. The Company will also participate in one-on-one meetings.7th Annual Evercore ISI HealthCONx Conference - December 3-5, 2024Format: Fireside ChatDay/Time: Tuesday, December 3 at 8:45 A.M. ETWebcast: https://wsw.com/webcast/evercore44/ptgx/2402505If you are interested in meeting with the Protagonist team during the conference, please reach out to your Evercor
Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases."We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information belowNEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results.Conference Call and Webcast DetailsThe dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are:US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274The webcast link for the event can
NEWARK, CA / ACCESSWIRE / November 18, 2024 / Protagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor in plaque psoriasisICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24ICONIC-TOTAL achieved its primary endpoint of IGA score of 0 or 1 at week 16 in patients with plaque psoriasis in difficult-to-treat areasProtagonist has earned a $165 million milestone under the terms of recently amended agreement, inclusive of $50 million in accelerated pay
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $72.00
Goldman initiated coverage of Protagonist Therapeutics with a rating of Neutral and set a new price target of $47.00
BMO Capital Markets initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $62.00
Wedbush initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $58.00
TD Cowen initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $65.00
Truist initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $60.00
CapitalOne initiated coverage of Protagonist Therapeutics with a rating of Overweight and set a new price target of $32.00
Jefferies resumed coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $40.00 from $30.00 previously
JMP Securities initiated coverage of Protagonist Therapeutics with a rating of Mkt Outperform and set a new price target of $21.00
BTIG initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $55.00
This live feed shows all institutional transactions in real time.
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
Live Leadership Updates
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I spaceNEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery,
NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 3, 2024 S&P SmallCap 600 Addition Protagonist Therapeutics PTGX Health Care S&P SmallCap 600 Deletion Encore Wire WIRE Industrials For more information a
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
NEWARK, CA / ACCESSWIRE / October 30, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Daniel N. Swisher, Jr. to its Board of Directors. Mr. Swisher recently retired as President and Chief Operating Officer of Jazz Pharmaceuticals, a position he held since 2018.Commenting on this appointment, Mr. Swisher remarked, "I am honored to join the Board of Directors at Protagonist at this exciting time for the Company. With two late-stage assets in Phase 3 development among its array of prospective value drivers - JNJ-2113, partnered with Janssen, and rusfertide, which is wholly owned - the growth opportunities for Protagonist are sign
Accomplished hematologist-oncologist will provide medical, clinical development, and strategic operational leadership to the ongoing rusfertide Phase 3 development program NEWARK, Calif., Nov. 2, 2022 /PRNewswire/ -- Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Arturo Molina, M.D., M.S., F.A.C.P. to the role of Chief Medical Officer, effective November 7, 2022. "We are extremely pleased to welcome Dr. Molina to Protagonist as our Chief Medical Officer," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist. "As a widely respected hematologist-oncologist and practicing physician, he brings a wealth of ex
NEWARK, Calif., March 28, 2022 /PRNewswire/ -- Protagonist Therapeutics (NASDAQ:PTGX) today announced the appointment of Asif Ali as Executive Vice President and Chief Financial Officer (CFO). In this role, Asif's responsibilities will extend across all finance-related functions within the Company, including financial planning and analysis, taxation, accounting and financial reporting, finance operations, investor relations, and strategic partnership-related financings. "I am extremely pleased to welcome Asif to Protagonist as our new CFO," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist. "His track record of success includes leadership and execution of the
NEWARK, Calif., Sept. 7, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Scott Plevy, M.D., to the role of Executive Vice President and Therapeutic Head, Gastroenterology. Dr. Plevy will oversee clinical operations and development of Protagonist's ongoing and future programs in gastrointestinal (GI) diseases, including PN-943, an investigational drug candidate currently in a Phase 2 study in ulcerative colitis. "Scott is a global thought leader whose translational and clinical research in gastroenterology and immunology has contributed significantly to the development of drugs for gastrointestinal diseas
NEWARK, Calif., Dec. 1, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 30, 2020, it issued an inducement award to Michelle Landolfi, Ph.D., the Company's recently hired Vice President, Regulatory Affairs, in accordance with the terms of Dr. Landolfi's employment offer letter. The award was granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020. The inducement award consists of an option to purchase 50,000 shares of Protagonist Therapeutics common stock and has a ten-year term. The exercise price of the option is $24.16, which was the per-share closing
Live finance-specific insights
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig
− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou
Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases."We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information belowNEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results.Conference Call and Webcast DetailsThe dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are:US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274The webcast link for the event can
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV)Takeda Will Make an Upfront Payment of $300 Million at ClosingPartnership Combines Protagonist's Leadership in Pharmaceutical Peptide Drug Development With Takeda's Commercial Expertise and 70-Plus Year Legacy of Driving Innovation Within the Rare Hematology CommunityProtagonist to Host Conference Call and Webcast Today at 4:30 PM ETOSAKA, JAPAN, CAMBRIDGE, MA, and NEWARK, CA / ACCESSWIRE / Januar
PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and endoscopic endpoints for efficacy, in the twice daily 150 mg dose arm Achieved clinical proof-of-concept and validation for oral, gut-restricted approach for ulcerative colitis via blockade of the alpha-4-beta-7-integrin pathway Plans underway for a registrational Phase 3 study anchored around twice daily 150 mg dose of PN-943, pending regulatory guidance Protagonist to host a conference call today at 6:00 p.m. ET NEWARK, Calif., April 25, 2022 /PRNewswire/ -- Protagonist Therapeutics (NASDAQ:PTGX) today announced topline results from the P
NEWARK, Calif., Oct. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on the Company's rusfertide clinical studies, announced on September 17, 2021. Per the FDA, dosing in all clinical studies of rusfertide may be resumed. The Company provided the FDA with all requested information as the basis for a Complete Response and subsequent removal of the clinical hold. In particular, the Company provided the requested individual patient clinical safety reports, updated the investigator brochure and patient informed consent forms, performed a comp
NEWARK, Calif., July 28, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced its entry into an amended collaboration agreement (the "Restated Agreement") with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, relating to research, development, manufacture and commercialization of multiple oral Interleukin (IL)-23 receptor antagonist drug candidates. The compounds currently in development are PTG-200, an oral IL-23 receptor antagonist in Phase 2 development for the treatment of Crohn's disease (CD), and PN-232 and PN-235, two second-generation oral IL-23 receptor antagonist candidates. PN-232
NEWARK, Calif., Dec. 2, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PTG-300 in the treatment of polycythemia vera, a rare disease characterized by the excessive production of red blood cells. PTG-300 is an injectable synthetic peptide mimetic of the natural hormone hepcidin that has demonstrated the ability to dramatically decrease the requirement for phlebotomy in an ongoing Phase 2 study in polycythemia vera patients. PTG-300 has previously received orphan drug designation for the treatment of polycythemia vera from the U.S. FDA. "Fast Track designation reflects t